Kids & teens (for parents) · Texas
Studies for children and teens in Texas
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
128 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Carrollton, TX + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingPhase 1Overnight stay mentioned
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics Inc
- Location
- DeSoto, TX + 3 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingHealthy volunteers
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
Mead Johnson Nutrition
- Location
- Richmond, TX + 9 other US sites
- Eligibility basics
- Ages 0 mo–0 mo
- RecruitingHealthy volunteersPhase 3
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Pfizer
- Location
- Brownsville, TX + 101 other US sites
- Eligibility basics
- Ages 1 mo–7 mo
- RecruitingHealthy volunteersPhase 3
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Sanofi
- Location
- Edinburg, TX + 13 other US sites
- Eligibility basics
- Ages 1 mo–2 mo
- RecruitingHealthy volunteersPhase 3
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
Pfizer
- Location
- Corpus Christi, TX + 49 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
GlaxoSmithKline
- Location
- Frisco, TX + 14 other US sites
- Eligibility basics
- Ages 1–6
- RecruitingHealthy volunteersPhase 3
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Dallas, TX + 14 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Beaumont, TX + 46 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- Houston, TX + 12 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteers
Flourish: Exploring the Early Infant Gut Microbiome
Seeding Inc
- Location
- Austin, TX
- Eligibility basics
- Ages 0 mo–4 mo
- RecruitingHealthy volunteers
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
SightGlass Vision, Inc.
- Location
- Beaumont, TX + 13 other US sites
- Eligibility basics
- Ages 6–8
- RecruitingHealthy volunteersPhase 3
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
ARJ Medical, Inc.
- Location
- El Paso, TX + 2 other US sites
- Eligibility basics
- Ages 3–17
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Fort Worth, TX + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche
- Location
- Houston, TX + 10 other US sites
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen
- Location
- Austin, TX + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Biogen
- Location
- Flower Mound, TX + 2 other US sites
- Eligibility basics
- Ages 0 mo–1 mo
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- El Paso, TX + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
AbbVie
- Location
- Dallas, TX + 11 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
BioMarin Pharmaceutical
- Location
- Dallas, TX + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Bristol-Myers Squibb
- Location
- Houston, TX + 11 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Amarillo, TX + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Sanofi
- Location
- Dallas, TX + 9 other US sites
- Eligibility basics
- Ages 1–11 · Men only
- RecruitingPhase 3
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Houston, TX + 10 other US sites
- Eligibility basics
- Ages 3–12